The majority of protein molecules must fold into defined three-dimensional structures to acquire functional activity. However, protein chains can adopt a multitude of conformational states, and their biologically active conformation is often only marginally stable. Metastable proteins tend to populate misfolded species that are prone to forming toxic aggregates, including soluble oligomers and fibrillar amyloid deposits, which are linked with neurodegeneration in Alzheimer and Parkinson disease, and many other pathologies. To prevent or regulate protein aggregation, all cells contain an extensive protein homeostasis (or proteostasis) network comprising molecular chaperones and other factors. These defense systems tend to decline during aging, facilitating the manifestation of aggregate deposition diseases. This volume of the Annual Review of Biochemistry contains a set of three articles addressing our current understanding of the structures of pathological protein aggregates and their associated disease mechanisms. These articles also discuss recent insights into the strategies cells have evolved to neutralize toxic aggregates by sequestering them in specific cellular locations. Proteins are the most versatile macromolecules. The proteomes of mammalian cells typically comprise between 10,000 and 20,000 different proteins. To maintain proteome integrity and cellular health, protein synthesis, folding, and degradation must be in proper balance and the abundance of each protein species carefully controlled. The information that specifies the compactly folded structure of a protein, required for its biological activity, is encoded in the linear amino acid sequence of the newly synthesized polypeptide chain (1), which may be up to several thousand amino acids in length. However, the number of conformations even a small polypeptide of ∼100 amino acids can adopt is astronomically large (∼10 30 ) (2). Moreover, the biologically active conformation (the native state), though thermodynamically favorable, is often only marginally stable under physiological conditions. It is not surprising, therefore, that the folding process is error prone, giving rise to misfolded states and off-pathway aggregates (Figure 1) . Over the last two decades it has become clear that many proteins require assistance by so-called molecular chaperones to fold efficiently and at a biologically relevant rate (3). Different chaperone proteins accompany the nascent polypeptide chain during translation on the ribosome and subsequent folding to prevent 
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Protein chains populate a range of interconvertible conformations during initial folding and throughout their lifetime in the cell. Molecular chaperones are key players in the cellular proteostasis network and serve to maintain proteome balance. They promote the folding of newly synthesized proteins, maintain proteins in their native conformations, and prevent the formation of toxic aggregates. Chaperones also cooperate with protein degradation machineries (the proteasome system and autophagy) in removing misfolded and aggregated proteins. (or reverse) misfolding and aggregation. These chaperones typically act by transiently shielding the hydrophobic amino acid residues that are exposed by proteins in their non-native conformations but are buried in the native state. They cooperate with machineries of protein degradation in a large protein homeostasis (or proteostasis) network (4) (5) (6) . Aberrant folding has been linked to a rapidly expanding list of pathologies. Two groups of these diseases must be distinguished: loss-of-function and toxic gain-of-function diseases. The first group of diseases is characterized by protein dysfunction resulting from mutations (single nucleotide polymorphisms) that may render proteins metastable and prone to degradation, as in the case of cystic fibrosis and a wide range of metabolic defects (7) . In the disorders of the second group, metastable proteins undergo aggregation in a process associated with cellular toxicity. These pathologies include the neurodegenerative diseases that cripple our aging societies, most prominently Alzheimer disease (AD) and Parkinson disease (PD), as well as type II diabetes and certain forms of heart disease and cancer. Aggregation may be caused by heritable mutations in disease proteins, as in the case of Huntington disease (HD) and in early onset AD and PD. However, the majority of cases are stochastic and manifest in an age-dependent manner, apparently facilitated through a decline in the capacity of the proteostasis network that occurs during aging (6, 8, 9) . Initially viewed as a nuisance by researchers studying protein folding, aggregation has emerged as a process of enormous medical relevance.
How do aggregates form and what are their structural properties? Partially folded or misfolded proteins typically expose hydrophobic amino acid residues and regions of unstructured polypeptide backbone to the solvent, features that drive the concentration-dependent formation of aggregates rich in β-sheet structure (Figure 1) . Whereas during folding hydrophobic forces operate within the molecule to stabilize its compact core, they act between molecules in aggregation. Although the majority of aggregates are amorphous, a subset of non-native proteins aggregate to so-called amyloid fibrils, which are structurally defined by β-strands running perpendicular to the long fibril axis (cross-β structure) (10). This structural pattern was first reported by the biophysicist William Astbury in 1935 (11) in poached egg white, the classic protein aggregate commonly encountered on the breakfast table. The formation of fibrillar aggregates and their deposition within and around cells are the hallmark of age-dependent neurodegenerative diseases. As noted in the article by Chiti & Dobson (12) , many amyloid-forming proteins are secreted and form deposits in the extracellular space of the nervous system and various organs. Relatively few amyloidogenic polypeptides are cytosolic and form intracellular inclusions. These include α-synuclein and tau, whose aggregation is linked with PD and AD, respectively, as well as the proteins containing expanded polyglutamine stretches that cause HD and various ataxias. Interestingly, amyloid-forming disease proteins are often relatively small (∼100 amino acids in length) and many are intrinsically disordered in their nonaggregated states, including α-synuclein and tau. No significant sequence similarities have been found among these proteins, consistent with the view that many proteins have an intrinsic ability to undergo fibrillar β-sheet aggregation (12) (13) (14) . Amyloid fibrils are typically 7-13 nm in diameter, as observed by electron microscopy, and often several microns in length. They are generally composed of a few protofilaments that twist around each other or associate laterally as flat ribbons. Remarkably, the fibrils display a tensile strength that approaches that of steel (12) , which is attributed primarily to their extended arrangement of hydrogen-bonded β-sheets. Indeed, the amyloid form of a protein molecule can be even more stable than the native state.
Important insights into the interactions occurring in amyloid fibrils have been provided by cryo-electron microscopy, solid-state NMR analysis, and X-ray diffraction studies of microcrystalline arrays of short peptides. As reviewed by Eisenberg & Saway (14) , a large number of amyloid microcrystals have now been studied at high resolution using highly focused X-ray microbeams. These structures revealed, among other features, the in-register alignment of the β-strands in the β-sheet to optimize the intermolecular interactions and the tight interdigitation of the side chains within such pairs. The use of small peptide segments able to form amyloid fibrils was critical in overcoming the challenge that the twisting architecture of fibrils otherwise presents to forming crystals. The first such crystal was of a seven-residue segment of the amyloid-forming yeast prion protein Sup35 with the sequence GNNQQNY (15) . In these crystals, the amyloid protofilament consists of two flat β-sheets forming a so-called steric zipper and extending throughout the length of the crystal, some 50,000 layers of short segments. This initial structure allowed the identification of amyloidogenic segments in other proteins, which were shown to form fibrils in vitro. Based on these analyses, structural features enabling amyloid formation are widespread in the proteome. Why amyloid aggregation is so toxic to cells, especially to neurons, is only partially understood. Importantly, the toxic effects of aggregation underlie common structural properties of the aggregates and may be entirely unrelated to the normal function of the affected protein (gain of toxic function). Before assembling to insoluble end-stage fibrils, the disease proteins often aggregate to soluble oligomers that are widely considered the primary toxic species (Figure 1) . The oligomers expose sticky surfaces (hydrophobic amino acid residues and unpaired β-strands), features that confer the ability to disturb phospholipid bilayers (12) and engage in aberrant interactions with multiple key cellular proteins (16, 17) . These dangerous surfaces are largely buried in the regular structure of the fibrils, explaining why fibrils are far less interactive than soluble oligomers (17) . Note, however, that fibrillar aggregates are by no means inert and, although less toxic, contribute to pathology by stably sequestering key cellular factors and by generating oligomers through fragmentation and secondary nucleation (12, 16) . The proteins targeted by toxic aggregates are often themselves metastable; they are typically enriched in intrinsically unstructured regions and sequences of low amino acid complexity, characteristic features of many RNA-binding proteins (16, 17) . Accordingly, protein aggregation interferes with nucleocytoplasmic RNA transport and RNA homeostasis (18, 19) . Importantly, multiple studies have shown that the aggregates can inhibit protein degradation by the proteasome and autophagy systems (6) and can sequester critical chaperone components (20-22). Aggregation therefore directly interferes with general protein quality control and is both a symptom and a cause of proteostasis decline.
Aggregate management is critical in determining cell viability and the life span of model organisms. Proteins have been optimized during evolution to maintain solubility at their physiological concentrations (23). Thus, even a modest increase in abundance, as might be caused by age-dependent proteome imbalance or that may be due to aneuploidy, will result in loss of solubility (24, 25). Recent studies revealed that an integral part of the cellular management of misfolded proteins is their spatial sequestration into several defined compartments. As discussed in the article by Frydman and colleagues (26), protein aggregation in the cell differs fundamentally from aggregation in the test tube in that cells contain intricate machineries that actively sequester surplus and misfolded proteins into transient or stable deposits when their timely degradation fails. These mechanisms, which involve specific chaperone proteins like the small heat shock protein Hsp42 (27), have apparently evolved to reduce the toxic effects exerted by soluble oligomers (28). One of the first compartments discovered in yeast cells was termed the insoluble protein deposit (IPOD) (29). The IPOD is thought to terminally sequester toxic amyloid and prion proteins in the cell periphery near the vacuole (26) and is likely equivalent to the perinuclear aggresome described in mammalian cells as a site of aggregate sequestration (30). Compartments for the transient sequestration of misfolded proteins are the so-called Q-bodies and the juxtanuclear quality control compartment ( JUNQ) (26). Q-bodies are small and form immediately upon protein misfolding, for example, under stress conditions. They concentrate in the JUNQ if their degradation by the ubiquitin proteasome system fails. Cytosolic misfolded proteins may also be 24 Hartl routed to an intranuclear quality control compartment (INQ) (31), consistent with the nucleus having an important role in quality control and degradation of cytosolic proteins (3, 21) . Taken together, the three articles in this volume highlight the enormous progress that has been made in recent years in defining the structures of pathological protein aggregates and their mechanisms of toxicity. Along with these investigations, understanding how an effective proteostasis network deals with misfolded proteins and why these defense mechanisms decline during aging will be important in finding ways to delay neurodegeneration and prolong the healthy life span. After all, we all want to get old, but no one wants to age.
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